

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Intervet Inc.
USDA Vet Biologics Establishment Number	165A
Product Code	19N1.20
True Name	Bovine Coronavirus Vaccine, Modified Live Virus
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Bovilis Coronavirus - Merck Animal Health Bovilis Coronavirus - No distributor specified
Date of Compilation Summary	August 05, 2021

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy								
Pertaining to	Bovine Co	oronavirus (BCV)							
Study Purpose	To demon	strate effectivenes	s against enteric di	sease caused by	y BCV.				
Product	One dose	administered by th	e intranasal route						
Administration									
Study Animals	44, 3-5 da	y old calves in 3 c	ohorts, distributed	equally into va	ccinates &				
	controls.	Controls received a	product-matched	placebo. Each	cohort was				
	vaccinated	d at different times	based on shipping	dates.					
Challenge	Calves we	ere challenged on t	he same day with H	BCV approxim	ately 4				
Description	weeks following the last cohort vaccination (Study Day 36).								
Interval	All calves	were observed for	signs of enteric di	sease (diarrhea	a) for 15 days				
observed after	post-chall	enge.							
challenge									
Results	Calves were considered positive for enteric disease if they had a diarrhea								
	score >1 for two or more consecutive days post-challenge.								
	Number	of vaccinates and	controls (out of th	e total) that a	re positive				
	for enteri	c disease.		<u>*</u>	<u>+ + +</u>				
	Cohort	Product	Challenge in	Vaccinates	Controls ^{**}				
			D A		Controls				
		Administration	Days after		Controls				
		Administration	Days after Product		Controls				
		Administration	Days after Product Administration						
	1	Administration SD ^{***} 0	Days after Product Administration 33	5/8	4/7				
	1 2	Administration SD ^{***} 0 SD 3	Days afterProductAdministration3329	5/8 2/8	4/7 8/10				
	1 2 3	Administration SD ^{***} 0 SD 3 SD 7	Days afterProductAdministration332926	5/8 2/8 1/4	4/7 8/10 4/5				
	1 2 3 <i>Total</i>	Administration SD ^{***} 0 SD 3 SD 7	Days afterProductAdministration332926	5/8 2/8 1/4 8/20	4/7 8/10 4/5 16/22				
	1 2 3 <i>Total</i> * 2 vacc	Administration SD ^{***} 0 SD 3 SD 7 inates were excluded f	Days after Product Administration 33 29 26	5/8 2/8 1/4 8/20 challenge due to b	4/7 8/10 4/5 16/22 unrelated				
	1 2 3 <i>Total</i> * 2 vacc causes ** 2 cont	Administration SD ^{***} 0 SD 3 SD 7 inates were excluded f s.	Days after Product Administration 33 29 26 From the study prior to schallenge due to enter	5/8 2/8 1/4 8/20 challenge due to r	4/7 8/10 4/5 16/22 unrelated				
	1 2 3 Total * 2 vacc causes ** 2 cont immunoh	Administration SD ^{***} 0 SD 3 SD 7 inates were excluded f s. rols died 12 days post- istochemical staining	Days after Product Administration 33 29 26 From the study prior to challenge due to enter to BCV on colon tissue	5/8 2/8 1/4 8/20 challenge due to r itis with mild to n e.	4/7 8/10 4/5 16/22 unrelated moderate				
	1 2 3 Total * 2 vacc causes ** 2 cont immunoh ***SD is	Administration SD ^{***} 0 SD 3 SD 7 inates were excluded f s. rols died 12 days post- istochemical staining Study Day	Days after Product Administration 33 29 26 From the study prior to challenge due to enter to BCV on colon tissue	5/8 2/8 1/4 8/20 challenge due to r itis with mild to n e.	4/7 8/10 4/5 16/22 unrelated noderate				
	1 2 3 <i>Total</i> * 2 vacc causes ** 2 cont immunoh ***SD is	Administration SD ^{***} 0 SD 3 SD 7 inates were excluded f s. rols died 12 days post- istochemical staining Study Day	Days after Product Administration 33 29 26 From the study prior to challenge due to enter to BCV on colon tissue	5/8 2/8 1/4 8/20 challenge due to r itis with mild to n e.	$\frac{4/7}{8/10}$ $\frac{4/5}{16/22}$ unrelated moderate				
USDA Approval	1 2 3 <i>Total</i> * 2 vacc causes ** 2 cont immunoh ***SD is 02/17/201	Administration SD ^{***} 0 SD 3 SD 7 inates were excluded f s. rols died 12 days post- istochemical staining Study Day 5	Days after Product Administration 33 29 26 From the study prior to challenge due to enter to BCV on colon tissue	5/8 2/8 1/4 8/20 challenge due to to itis with mild to n e.	4/7 8/10 4/5 16/22 unrelated noderate				

Enteric at	sease In cal	ves post c	nallen	a De M					Disch	Control of	* on Dou	Dect Ch	n openelle	AP DCV						
Animal ID	Treatment	Cohort	-2	-	0	-	2	3	4	5	6 6		allelige w	6	10	11	12	13	14	15
378	Control	-						2	-	m	-									
379	Control	-							m	m	2	m	m							
380	Control	ļ												-						
381	Control	1					-	3	3	3		e.		2	2					
382	Control	1						2	2	2	3	3		3		2	2			
383	Control	t						-	2	2	2									
384	Control	Ļ					2	1			2			2		Ļ				
393	Control	2							2	3	33		3	3	2	2				
394	Control	2						£	m	m	-			2	2		-			
395	Control	2								m	-	2	2							
396	Control	2						e	e	m	m		m	-	2	2	-	e	ę	-
397	Control	2					-	e	2	m	m	m	m	-	-					
398	Control	2																		
399	Control	2						2	-	~	m	2		-			e,			
400	Control	2							-	2							2			
401	Control	2					m	ñ	m	m	2		m	m	-					
402	Control	2						e			2	-	m	m	2		-	-		
412	Control	ę						ns		m	m	-	m	m		2	2		-	
413	Control	ę						m	2	~		~			~					
414	Control	m					2	2	m	2	~	m				m	2			
415	Control	m						2	m	m	-	m	2	m	2	2				
416	Control	£											2				33			
385	Vac	-		-	-		2					-	2	-		2	+	+	-	-
386	Vac	-						ę	~	~			2	-						
387	Vac	Ļ																		
388	Vac	-						ę	m	~	m	-	m	m	-	-	-	ę		
389	Vac	F						÷	m	m	m				-					
390	Vac	F						2	2		-		-			-				
391	Vac	÷								2	-	2		-						
392	Vac	1						2			2	3	2	1			1			
403	Vac	2					+	3		3				2		1	1	1		
404	Vac	2						2									-			
405	Vac	2								2				m						
407	Vac	2						2	æ	æ	e									
408	Vac	2						2							+		1			
409	Vac	2					-	-												
410	Vac	2									2	2	-	-	-					
411	Vac	2							us			m		m				-		
417	Vac	m					-				m									
419	Vac	m									2	2								
420	Vac	3																		
421	Vac	3											1	1			1			
*(Mild, 1)	-more runny	than norm?	al but st	ill so	me sen	f bilosit	onn. ()	Ioderat	e, 2)=ve	erv little	solid :	materia	1. (Seve	ere, 3)=	primari	lv wate	erv, littl	le to no	solid	
material										•			,							

165A

Study Type	Safety							
Pertaining to	ALL							
Study Purpose	To demonstra	te safet	y under typ	oical field con	ditions			
Product	One dose adn	ninistere	ed by the in	ntranasal route	;			
Administratio			•					
n								
Study Animals	930 calves (6	19 vacc	inates & 3	11 controls) ra	inging in ag	ge from 1	l day to 4	
v	months, locat	ed at 3 d	lifferent si	tes. $1/3$ of cal	ves were o	f minim	um ages	
	recommende	d for pro	duct admi	nistration.			U	
Challenge	N/A	1						
Description								
Interval	No challenge. All calves were observed once between 1- and 4-hours							
observed after	following vac	cination	and then	daily through	21 days po	st-vaccii	nation.	
challenge	ε			, 0	J 1			
Results								
	Adverse Eve	nt (AE)	Summar	V				
	Crown Age # Calves # of Calves with AE's							
	Group (days) Enrolled Respiratory* Enteric** Other [¥] Mortality†							
						-		
	X 7	≤ 7	233	65	156	0	17	
	Vaccinates	> 7	200	21	1	1	2	
	>7 380 21 1 1 2 Controls (Placebo) ≤ 7 119 30 70 2 8 (Placebo) >7 192 7 1 0 0 *Respiratory disease was due to Boyine Coronavirus Histophilus somni Infectious							
	Bovine Rhinotracheitis, <i>Pasteurella multocida</i> , or <i>Mycoplasma bovis</i> . Pathogens may have been detected prior to vaccination and at the time of the adverse event.							
	**Enteric disease was due to Bovine Coronavirus, Bovine Rotavirus, <i>Crvptococcus</i>							
	<i>sp</i> , and <i>E. coli</i> . Pathogens may have been detected prior to vaccination and at the							
	time of the adv	verse eve	nt.					
	¥ Other includ	ed bloati	ng, lamenes	ss, and not eatir	ng and affirn	ned by lic	censee to not	
	be related to a	lministra	tion of the	vaccine.	-	-		
	†Mortality was	s not rela	ted to vacci	ine administrati	on as affirm	ed by the	e licensee.	
-								
USDA	03/08/2016							
Annroval Date								